DDInter1340 DDInter147
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Omeprazole {u} (Compound) binds {v} (Gene) ATP4A
ATP4A {u} (Gene) is bound by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Axitinib
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Axitinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole (Compound) resembles Esomeprazole (Compound) and Es
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Omeprazole (Compound) binds ATP4A (Gene) and ATP4A (Gene) is bound by Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Axitinib